Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alto Neuroscience, Inc. Common Stock
(NY:
ANRO
)
4.000
+0.110 (+2.83%)
Official Closing Price
Updated: 7:00 PM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
188,801
Open
3.860
Bid (Size)
3.810 (1)
Ask (Size)
4.290 (1)
Prev. Close
3.890
Today's Range
3.850 - 4.070
52wk Range
3.560 - 24.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
December 16, 2024
Via
ACCESSWIRE
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
December 16, 2024
Via
Benzinga
Performance
YTD
-80.68%
-80.68%
1 Month
-9.50%
-9.50%
3 Month
-69.90%
-69.90%
6 Month
-61.76%
-61.76%
1 Year
-80.68%
-80.68%
More News
Read More
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
December 15, 2024
Via
ACCESSWIRE
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
December 14, 2024
Via
ACCESSWIRE
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud
December 13, 2024
Via
ACCESSWIRE
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
December 12, 2024
Via
ACCESSWIRE
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
December 11, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
November 04, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
November 04, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm
October 27, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Nasdaq Down 2%; US Crude Stocks Increase
October 23, 2024
Via
Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
October 23, 2024
Via
Benzinga
Gold Moves Lower; AT&T Earnings Top Views
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 23, 2024
Via
Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
October 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 23, 2024
Via
Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
October 23, 2024
Via
Benzinga
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm
October 22, 2024
From
The Schall Law Firm
Via
Business Wire
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
October 22, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
September 04, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
September 03, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.